1. Home
  2. JYNT vs CGEN Comparison

JYNT vs CGEN Comparison

Compare JYNT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • CGEN
  • Stock Information
  • Founded
  • JYNT 2010
  • CGEN 1993
  • Country
  • JYNT United States
  • CGEN Israel
  • Employees
  • JYNT N/A
  • CGEN N/A
  • Industry
  • JYNT Multi-Sector Companies
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JYNT Miscellaneous
  • CGEN Health Care
  • Exchange
  • JYNT Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • JYNT 170.1M
  • CGEN 167.4M
  • IPO Year
  • JYNT 2014
  • CGEN 2000
  • Fundamental
  • Price
  • JYNT $11.19
  • CGEN $1.46
  • Analyst Decision
  • JYNT Strong Buy
  • CGEN
  • Analyst Count
  • JYNT 2
  • CGEN 0
  • Target Price
  • JYNT $15.50
  • CGEN N/A
  • AVG Volume (30 Days)
  • JYNT 42.7K
  • CGEN 245.6K
  • Earning Date
  • JYNT 08-07-2025
  • CGEN 08-06-2025
  • Dividend Yield
  • JYNT N/A
  • CGEN N/A
  • EPS Growth
  • JYNT N/A
  • CGEN N/A
  • EPS
  • JYNT N/A
  • CGEN N/A
  • Revenue
  • JYNT $52,789,479.00
  • CGEN $27,589,000.00
  • Revenue This Year
  • JYNT $9.48
  • CGEN N/A
  • Revenue Next Year
  • JYNT $11.15
  • CGEN $105.77
  • P/E Ratio
  • JYNT N/A
  • CGEN N/A
  • Revenue Growth
  • JYNT 71.05
  • CGEN N/A
  • 52 Week Low
  • JYNT $9.58
  • CGEN $1.13
  • 52 Week High
  • JYNT $13.47
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 46.48
  • CGEN 37.69
  • Support Level
  • JYNT $10.72
  • CGEN $1.35
  • Resistance Level
  • JYNT $11.75
  • CGEN $1.50
  • Average True Range (ATR)
  • JYNT 0.37
  • CGEN 0.08
  • MACD
  • JYNT -0.05
  • CGEN -0.01
  • Stochastic Oscillator
  • JYNT 44.34
  • CGEN 37.93

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: